Amneal Pharmaceuticals, Inc. (AMRX): A Bull Case Theory

We came across a bullish thesis on Amneal Pharmaceuticals, Inc. on Value investing subreddit by nknown10. In this article, we will summarize the bulls’ thesis on AMRX. Amneal Pharmaceuticals, Inc.'s share was trading at $10.01 as of September 30th. AMRX’s trailing P/E was 975.00 according to Yahoo Finance.

Amneal Pharmaceuticals (AMRX) presents a compelling long-term investment opportunity, supported by both strong operational execution and visionary leadership. The stock, currently trading at a discount to peers on EV/EBITDA and P/E multiples, has significant upside potential if execution continues, with re-rating toward peer valuations alone justifying a target range of $12–$15 per share. The company’s capital structure has materially improved, driven by stronger operating cash flow, refinancing at lower rates, and consistent debt paydown, alleviating a historical overhang that weighed on performance post-merger.

Amneal is building a robust pipeline, with over 100 ANDAs pending, including complex generics that are more difficult for competitors to enter, and recent FDA approvals and product launches, such as GLIADEL Wafer and biosimilars like Releuko and Fylnetra, underscore the company’s execution capabilities. Beyond financials and pipeline, leadership is a critical differentiator for Amneal. Co-CEOs Chirag and Chintu, who were instrumental in the company’s initial growth, returned after a period of severe stock underperformance and have successfully reassembled a strong management team aligned with a clear strategic vision.

Their leadership has driven consistent growth over the last five years, revitalizing the company’s culture and operational focus. With these factors combined—undervalued stock, improving financial health, a differentiated product pipeline, and exceptional leadership—Amneal offers a high-conviction investment case with meaningful upside potential, making it attractive for investors seeking both growth and resilience in the specialty and affordable medicines space.

Previously we covered a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) by Kontra in April 2025, which highlighted the company’s structural improvements, cost optimization, and growth in branded drugs and biosimilars. The stock has appreciated approximately 44% since our coverage. The thesis still stands as TEVA’s undervaluation and pipeline remain compelling. unknown10 shares a similar perspective but emphasizes Amneal’s execution, leadership, and ANDA pipeline.

Amneal Pharmaceuticals, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 28 hedge fund portfolios held AMRX at the end of the second quarter which was 30 in the previous quarter. While we acknowledge the potential of AMRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.